Skip to contentSkip to footer
How we helped
We advised Advanz Pharma on its appeal of one of the two infringement decisions by the CMA in relation to the supply of hydrocortisone and liothyronine tablets. Following several investigations into the pharmaceutical sector, the CMA fined suppliers of hydrocortisone tablets over £260 million and suppliers of liothyronine tablets over £100 million in 2021, for alleged breaches of competition law. Specifically, the CMA found the suppliers engaged in excessive pricing and so-called “pay-for-delay” agreements, by which potential competitors agree to stay out of a market in return for a payment.
Our expert produced an expert report focusing on questions of market definition in the hydrocortisone proceedings and provided testimony to the Competition Appeal Tribunal.